Premium
A randomized, placebo‐controlled, double‐blind trial of ondansetron in renal itch
Author(s) -
Murphy M.,
Reaich D.,
Pai P.,
Finn P.,
Carmichael A.J.
Publication year - 2003
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2003.05172.x
Subject(s) - ondansetron , placebo , medicine , nausea , anesthesia , visual analogue scale , randomized controlled trial , surgery , alternative medicine , pathology
Summary Background Renal itch is a relatively common and distressing problem for patients with chronic renal failure. Ondansetron, a serotonin type 3 receptor antagonist was developed for relief of chemotherapy induced nausea. Recently, anecdotal reports describe relief of renal itch with ondansetron. Objectives We performed a double‐blind randomized placebo‐controlled trial to objectively assess the effectiveness of ondansetron in renal itch. Patients and methods With approval from the local ethical committee, 24 patients on haemodialysis were enrolled in the trial. On a random basis 14 patients were blindly allocated to the ondansetron–placebo sequence and 10 to the placebo–ondansetron sequence. Baseline values for itch were obtained for 7 days before the treatment period and there was a 7‐day washout between the treatment periods. During the treatment patients received either 8 mg of ondansetron three times a day or a placebo tablet three times a day for 2 weeks. Patients were asked to record the severity of their pruritus on a visual analogue scale (VAS) twice a day. At the end of the study patients were asked blindly which treatment they had preferred. Results Seventeen patients completed the trial. Pruritus decreased by 16% (95% CI: 0·5–32%) during active treatment and by 25% (95% CI: 9–41%) during treatment with placebo. The change in VAS scores during treatment with ondansetron ( P = 0·04) and placebo ( P = 0·01) were both significant. Eleven patients expressed a preference, seven for placebo and four for ondansetron. Conclusions Our results show that ondansetron is no better than placebo in controlling renal itch.